Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients.

Author: Jiayi WU ¹ ; Weiqi GAO ¹ ; Xiaosong CHEN ¹ ; Chunxiao FEI ¹ ; Lin LIN ¹ ; Weiguo CHEN ¹ ; Ou HUANG ¹ ; Siji ZHU ¹ ; Jianrong HE ¹ ; Yafen LI ¹ ; Li ZHU ¹ ; Kunwei SHEN ²
Author Information

1. Comprehensive Breast Health Center, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
2. Comprehensive Breast Health Center, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. kwshen@medmail.com.cn.
Publication Type:Journal Article
Keywords: 21-gene assay; early breast cancer; prognosis; recurrence score
MeSH: Biomarkers, Tumor/genetics*; Breast Neoplasms/pathology*; Female; Humans; Neoplasm Recurrence, Local/pathology*; Neoplasm Staging; Prognosis; Receptor, ErbB-2/genetics*; Receptors, Estrogen
From: Frontiers of Medicine 2021;15(4):621-628
CountryChina
Language:English
Abstract: Multi-gene assays have emerged as crucial tools for risk stratification in early-stage breast cancer. This study aimed to evaluate the prognostic significance of the 21-gene recurrence score (RS) in Chinese patients with pN0-1, estrogen receptor-positive (ER